stockrow
Friday 6 November 2026
Export XGN’s income statement to Excel — free account
Exagen Inc.
XGN Healthcare Diagnostics & Research
Exagen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.6 million, up 19.7% from fiscal 2024.
- Revenue
- +15.9%
- EPS
- +38.1%
- Free cash flow
- +211.3%
- Total debt
- +6.44%
Quarter to June 2026, against a year earlier
6.02
1.58
−20.79%
Follow XGN
Alert me
Exagen Inc. (XGN) P/E ratio
Exagen Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 27 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BNR Burning Rock Biotech Limited Sponsored ADR compare | n/m |
| CSTL Castle Biosciences, Inc. compare | n/m |
| MYGN Myriad Genetics, Inc. compare | n/m |
| BDSX Biodesix, Inc. compare | n/m |
| IMDX Insight Molecular Diagnostics Inc. compare | n/m |
| QUCY Quantum Cyber N.V compare | n/m |
| FLGT Fulgent Genetics, Inc. compare | n/m |
| XGN Exagen Inc. | n/m |
| MDXHF MedX Health Corp. compare | n/m |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)